Abivax (ABVX) Projected to Post Quarterly Earnings on Monday

Abivax (NASDAQ:ABVX) will likely be posting its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($2.24) per share and revenue of $1.7950 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 23, 2026 at 7:00 AM ET.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. On average, analysts expect Abivax to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Abivax Stock Down 1.3%

Shares of NASDAQ ABVX opened at $115.50 on Monday. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -27.63 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The business has a 50-day moving average of $118.99 and a two-hundred day moving average of $109.10. Abivax has a 1 year low of $4.77 and a 1 year high of $148.83.

Wall Street Analysts Forecast Growth

ABVX has been the topic of several research analyst reports. Guggenheim reissued a “buy” rating and set a $175.00 target price on shares of Abivax in a research report on Thursday, December 18th. Oppenheimer set a $131.00 price target on Abivax in a report on Thursday, January 8th. Wedbush started coverage on shares of Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price target on the stock. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $142.00 target price on shares of Abivax in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Abivax currently has a consensus rating of “Moderate Buy” and an average target price of $134.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Millennium Management LLC increased its position in Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after purchasing an additional 56,235 shares during the period. Woodline Partners LP increased its position in Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after purchasing an additional 153,788 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Abivax during the 2nd quarter worth approximately $139,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.